WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company known for its work in virology, has revealed it will present its fourth quarter and year-end 2023 financial results on February 29, 2024. The Warminster, Pennsylvania-based company is developing a functional cure for chronic hepatitis B virus (cHBV) infection, a disease that affects millions worldwide.
The announcement will be made at 7:30 a.m. ET, followed by a conference call and webcast at 8:45 a.m. ET. Market watchers eagerly await these results as they will shed light on the company’s financial performance and provide updates on their groundbreaking therapeutic efforts against cHBV.
Arbutus is leveraging its extensive virology expertise to develop cutting-edge therapeutics aimed at delivering a functional cure for cHBV. By suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses, the company believes it can make significant strides toward curing the disease.
The company’s proprietary pipeline of compounds includes imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor. These two drugs are currently under clinical trials and have shown promising results.
Imdusiran has already generated meaningful clinical data demonstrating its impact on both surface antigen reduction and the reawakening of the HBV-specific immune response. It is currently in two Phase 2a combination clinical trials.
Meanwhile, AB-101 is being evaluated in a Phase 1a/1b clinical trial. As an oral PD-L1 inhibitor, it represents a novel approach to harnessing the body’s immune system to fight off cHBV infection.
With the upcoming financial report, investors and healthcare providers alike are keen to see how Arbutus’s financial health aligns with its ambitious objectives. Given the company’s potential to transform the lives of those living with cHBV, the results are poised to make waves in both the medical and financial spheres.
Interested parties can register for the conference call or access the live webcast through the Investors section of the Arbutus website. An archived webcast will also be available on the Arbutus website after the event for those unable to attend the live broadcast.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.